@article{oai:repository.lib.tottori-u.ac.jp:00005021,
 author = {Fukumoto, Yoji and Fukumoto, Yoji and Yamada, Yoshinori and Fukuda, Kenji and Saito, Hiroaki and Saito, Hiroaki and Tatebe, Shigeru and Tsujitani, Shunichi and Ikeguchi, Masahide and Ikeguchi, Masahide and Yamada, Yoshinori and Fukuda, Kenji and Tatebe, Shigeru and Tsujitani, Shunichi},
 issue = {1},
 journal = {Yonago Acta medica, Yonago Acta medica},
 month = {Mar},
 note = {Human fibroblast activation protein (FAP) is a 97-kDa surface glycoprotein expressed in tumor-associated fibroblasts. In this study, we immunohistochemically examined FAP levels in surgically resected gastric carcinomas and explored their association with clini-copathological findings and prognosis. Sections of paraffin-embedded specimens were obtained from 100 patients with advanced gastric cancer between 1989 and 2001 at our institution, and they were stained with an anti-FAP antibody. Expression of FAP was detected in 64 patients (64%). Lymphatic vessel invasion was observed in 90% of FAP-positive patients (P = 0.015). Blood vessel invasion was observed in 98% of FAP-positive patients (P < 0.001). The disease-specific 5-year survival rate of in the 64 patients with FAP-positive tumors (22%) was significantly lower than in the 36 patients with FAP-negative tumors (34%, P = 0.036). This indicates that vessel invasion is connected with the expression of FAP and that a positive finding of FAP confer a worse prognosis in the patients with gastric cancer.},
 pages = {21--25},
 title = {Clinical Findings on Fibroblast Activation Protein in Patients with Gastric Cancer},
 volume = {52},
 year = {2009}
}